{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T21:30:01Z","timestamp":1671658201052},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,10,11]],"date-time":"2006-10-11T00:00:00Z","timestamp":1160524800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1007\/s10549-006-9272-2","type":"journal-article","created":{"date-parts":[[2006,10,10]],"date-time":"2006-10-10T12:01:44Z","timestamp":1160481704000},"page":"95-104","source":"Crossref","is-referenced-by-count":13,"title":["The impact of breast cancer awareness and socioeconomic status on willingness to receive breast cancer prevention drugs"],"prefix":"10.1007","volume":"101","author":[{"given":"Peter A.","family":"Fasching","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunter","family":"von Minckwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorsten","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Schultz-Zehden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heike","family":"Beck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Lux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Meden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Kiechle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias W.","family":"Beckmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Paepke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,10,11]]},"reference":[{"key":"9272_CR1","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(02)09962-2","volume":"360","author":"J Cuzick","year":"2002","unstructured":"Cuzick J, Forbes J, Edwards R et al (2002) First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360:817\u2013824","journal-title":"Lancet"},{"key":"9272_CR2","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371\u20131388","journal-title":"J Natl Cancer Inst"},{"key":"9272_CR3","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0140-6736(98)85012-5","volume":"352","author":"T Powles","year":"1998","unstructured":"Powles T, Eeles R, Ashley S et al (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352:98\u2013101","journal-title":"Lancet"},{"key":"9272_CR4","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/S0140-6736(02)08159-X","volume":"359","author":"U Veronesi","year":"2002","unstructured":"Veronesi U, Maisonneuve P, Sacchini V et al (2002) Tamoxifen for breast cancer among hysterectomised women. Lancet 359:1122\u20131124","journal-title":"Lancet"},{"key":"9272_CR5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1006478317173","volume":"65","author":"JA Cauley","year":"2001","unstructured":"Cauley JA, Norton L, Lippman ME et al (2001) Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65:125\u2013134","journal-title":"Breast Cancer Res Treat"},{"key":"9272_CR6","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0140-6736(03)12342-2","volume":"361","author":"J Cuzick","year":"2003","unstructured":"Cuzick J, Powles T, Veronesi U et al (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296\u2013300","journal-title":"Lancet"},{"key":"9272_CR7","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","volume":"349","author":"PE Goss","year":"2003","unstructured":"Goss PE, Ingle JN, Martino S et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793\u20131802","journal-title":"N Engl J Med"},{"key":"9272_CR8","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","volume":"359","author":"ATAC Trialists","year":"2002","unstructured":"ATAC Trialists (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131\u20132139","journal-title":"Lancet"},{"key":"9272_CR9","doi-asserted-by":"crossref","unstructured":"Thurlimann B, for the BIG 1-98 Collaborative Group X: BIG 1-98 (2005) A prospective randomized double-blind double-dummy phase III study to evaluate letrozole as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast 14(Suppl 1):S3","DOI":"10.1016\/S0960-9776(05)80005-0"},{"key":"9272_CR10","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","volume":"350","author":"RC Coombes","year":"2004","unstructured":"Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081\u20131092","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"9272_CR11","first-page":"S7","volume":"88","author":"R Jakesz","year":"2004","unstructured":"Jakesz R, Kaufmann M, Gnant M et al (2004) Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2\u00a0years adjuvant tamoxifen: combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. Breast Cancer Res Treat 88(Suppl 1):S7","journal-title":"Breast Cancer Res Treat"},{"key":"9272_CR12","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1200\/JCO.2005.11.027","volume":"23","author":"J Cuzick","year":"2005","unstructured":"Cuzick J (2005) Aromatase inhibitors for breast cancer prevention. J Clin Oncol 23:1636\u20131643","journal-title":"J Clin Oncol"},{"key":"9272_CR13","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1200\/JCO.2000.18.6.1203","volume":"18","author":"LA Siminoff","year":"2000","unstructured":"Siminoff LA, Zhang A, Colabianchi N et al (2000) Factors that predict the referral of breast cancer patients onto clinical trials by their surgeons and medical oncologists. J Clin Oncol 18:1203\u20131211","journal-title":"J Clin Oncol"},{"key":"9272_CR14","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1200\/JCO.2001.19.6.1728","volume":"19","author":"PN Lara Jr","year":"2001","unstructured":"Lara PN Jr, Higdon R, Lim N et al (2001) Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol 19:1728\u20131733","journal-title":"J Clin Oncol"},{"key":"9272_CR15","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1046\/j.1523-5394.2002.101006.x","volume":"10","author":"ED Paskett","year":"2002","unstructured":"Paskett ED, Cooper MR, Stark N et al (2002) Clinical trial enrollment of rural patients with cancer. Cancer Pract 10:28\u201335","journal-title":"Cancer Pract"},{"key":"9272_CR16","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","volume":"291","author":"VH Murthy","year":"2004","unstructured":"Murthy VH, Krumholz HM, Gross CP (2004) Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 291:2720\u20132726","journal-title":"JAMA"},{"key":"9272_CR17","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/jnci\/djh193","volume":"96","author":"CP Gross","year":"2004","unstructured":"Gross CP, Murthy V, Li Y et al (2004) Cancer trial enrollment after state-mandated reimbursement. J Natl Cancer Inst 96:1063\u20131069","journal-title":"J Natl Cancer Inst"},{"key":"9272_CR18","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1200\/JCO.2005.00.430","volume":"23","author":"CP Gross","year":"2005","unstructured":"Gross CP, Krumholz HM (2005) Impact of managed care on cancer trial enrollment. J Clin Oncol 23:3811\u20133818","journal-title":"J Clin Oncol"},{"key":"9272_CR19","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1046\/j.1440-1622.1999.01608.x","volume":"69","author":"PM Ellis","year":"1999","unstructured":"Ellis PM, Butow PN, Simes RJ et al (1999) Barriers to participation in randomized clinical trials for early breast cancer among Australian cancer specialists. Aust NZ J Surg 69:486\u2013491","journal-title":"Aust NZ J Surg"},{"key":"9272_CR20","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1200\/JCO.2001.19.15.3554","volume":"19","author":"PM Ellis","year":"2001","unstructured":"Ellis PM, Butow PN, Tattersall MH et al (2001) Randomized clinical trials in oncology: understanding and attitudes predict willingness to participate. J Clin Oncol 19:3554\u20133561","journal-title":"J Clin Oncol"},{"key":"9272_CR21","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2004.03.005","volume":"22","author":"MS Simon","year":"2004","unstructured":"Simon MS, Du W, Flaherty L et al (2004) Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. J Clin Oncol 22:2046\u20132052","journal-title":"J Clin Oncol"},{"key":"9272_CR22","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/cncr.20792","volume":"103","author":"CP Gross","year":"2005","unstructured":"Gross CP, Filardo G, Mayne ST et al (2005) The impact of socioeconomic status and race on trial participation for older women with breast cancer. Cancer 103:483\u2013491","journal-title":"Cancer"},{"key":"9272_CR23","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1634\/theoncologist.7-1-60","volume":"7","author":"TJ Powles","year":"2002","unstructured":"Powles TJ (2002) Breast cancer prevention. Oncologist 7:60\u201364","journal-title":"Oncologist"},{"issue":"Suppl 1","key":"9272_CR24","first-page":"S52","volume":"267","author":"G Minckwitz von","year":"2002","unstructured":"von Minckwitz G, Prieshof B, Hofmann K et al (2002) Prevention with goserelin and ibandronate in premenopausal women with familial breast cancer risk: first experiences of the GISS study. Arch Gynecol Obstet 267(Suppl 1):S52","journal-title":"Arch Gynecol Obstet"},{"key":"9272_CR25","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1749-6632.1995.tb12146.x","volume":"768","author":"SW Vernon","year":"1995","unstructured":"Vernon SW, Yeomans AC, Frankowski R et al (1995) Behavioral and social factors that predict participation in the Breast Cancer Prevention Trial. Ann NY Acad Sci 768:300","journal-title":"Ann NY Acad Sci"},{"key":"9272_CR26","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/1097-0142(19950701)76:1<46::AID-CNCR2820760107>3.0.CO;2-B","volume":"76","author":"A Yeomans-Kinney","year":"1995","unstructured":"Yeomans-Kinney A, Vernon SW, Frankowski RF et al (1995) Factors related to enrollment in the breast cancer prevention trial at a comprehensive cancer center during the first year of recruitment. Cancer 76:46\u201356","journal-title":"Cancer"},{"key":"9272_CR27","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1006\/pmed.1998.0349","volume":"27","author":"AY Yeomans Kinney","year":"1998","unstructured":"Yeomans Kinney AY, Richards C, Vernon SW et al (1998) The effect of physician recommendation on enrollment in the Breast Cancer Chemoprevention Trial. Prev Med 27:713\u2013719","journal-title":"Prev Med"},{"key":"9272_CR28","first-page":"591","volume":"7","author":"A Yeomans Kinney","year":"1998","unstructured":"Yeomans Kinney A, Vernon SW, Shui W et al (1998) Validation of a model predicting enrollment status in a chemoprevention trial for breast cancer. Cancer Epidemiol Biomarkers Prev 7:591\u2013595","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"9272_CR29","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/jnci\/djh229","volume":"96","author":"S Wacholder","year":"2004","unstructured":"Wacholder S (2004) Bias in intervention studies that enroll patients from high-risk clinics. J Natl Cancer Inst 96:1204\u20131207","journal-title":"J Natl Cancer Inst"},{"key":"9272_CR30","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1055\/s-2000-9551","volume":"60","author":"S Paepke","year":"2000","unstructured":"Paepke S, Schubert R, Huttner C et al (2000) Breast cancer awareness and screening behavior: a cross-sectional analysis of 2110 women. Geburtshilfe Frauenheilkd 60:620\u2013624","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"9272_CR31","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/jnci\/81.24.1879","volume":"81","author":"MH Gail","year":"1989","unstructured":"Gail MH, Brinton LA, Byar DP et al (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879\u20131886","journal-title":"J Natl Cancer Inst"},{"key":"9272_CR32","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5","volume":"73","author":"EB Claus","year":"1994","unstructured":"Claus EB, Risch N, Thompson WD (1994) Autosomal dominant inheritance of early-onset breast cancer: implications for risk prediction. Cancer 73:643\u2013651","journal-title":"Cancer"},{"key":"9272_CR33","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1086\/301670","volume":"62","author":"G Parmigiani","year":"1998","unstructured":"Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145\u2013158","journal-title":"Am J Hum Genet"},{"key":"9272_CR34","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/sj.bjc.6602175","volume":"91","author":"AC Antoniou","year":"2004","unstructured":"Antoniou AC, Pharoah PP, Smith P et al (2004) The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 91:1580\u20131590","journal-title":"Br J Cancer"},{"key":"9272_CR35","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/sim.1668","volume":"23","author":"J Tyrer","year":"2004","unstructured":"Tyrer J, Duffy SW, Cuzick J (2004) A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23:1111\u20131130","journal-title":"Stat Med"},{"key":"9272_CR36","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1136\/jmg.40.11.807","volume":"40","author":"E Amir","year":"2003","unstructured":"Amir E, Evans DG, Shenton A et al (2003) Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 40:807\u2013814","journal-title":"J Med Genet"},{"issue":"Suppl","key":"9272_CR37","first-page":"S57","volume":"130","author":"PA Fasching","year":"2004","unstructured":"Fasching PA, Nestle-Kraemling C, Bani M et al (2004) Breast cancer risk assessment in clinical use: prediction of BRCA mutation and estimation of lifetime risk by BRCAPRO, MENDEL and the Tyrer\u2013Cuzick model. J Cancer Res Clin Oncol 130(Suppl):S57","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-006-9272-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-006-9272-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-006-9272-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T12:28:42Z","timestamp":1559219322000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-006-9272-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,11]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["9272"],"URL":"https:\/\/doi.org\/10.1007\/s10549-006-9272-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,11]]}}}